| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| M611781-5mg |
5mg |
期货  |
| |
| M611781-25mg |
25mg |
期货 |
|
| 别名 | 甲氟喹 |
|---|---|
| 英文别名 | 4-Quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-(+-)- | (+)-erythro-4-Quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)- | Mefloquina (INN-Spanish) | P01BC02 | MMV000014 | BIDD:PXR0166 | NCGC00161831-03 | XEEQGY |
| 规格或纯度 | Moligand™ |
| 英文名称 | mefloquine |
| 作用类型 | 拮抗剂 |
| 作用机制 | A 1 受体拮抗剂；A 2A 受体拮抗剂 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol |
| INCHI | 1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2/t12-,15+/m1/s1 |
| InChi Key | XEEQGYMUWCZPDN-DOMZBBRYSA-N |
| Smiles | C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O |
| Isomeric SMILES | C1CCN[C@H](C1)[C@H](C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O |
| 关联CAS | 51742-87-1,53230-10-7 |
| PubChem CID | 40692 |
| MeSH Entry Terms | Lariam;Mefloquine;Mefloquine Hydrochloride;Mephloquine;Ro 21 5998 001;Ro-21-5998-001;Ro215998001;WR 142,490;WR 177,602;WR-142,490;WR-177,602;WR142,490;WR177,602 |
| 分子量 | 378.310 g/mol |
|---|---|
| XLogP3 | 3.600 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 9 |
| 可旋转键计数Rotatable Bond Count | 2 |
| 精确质量Exact Mass | 378.117 Da |
| 单同位素质量Monoisotopic Mass | 378.117 Da |
| 拓扑极表面积Topological Polar Surface Area | 45.200 Ų |
| 重原子数Heavy Atom Count | 26 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 483.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 2 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Trenholme CM, Williams RL, Desjardins RE, Frischer H, Carson PE, Rieckmann KH, Canfield CJ. (1975) Mefloquine (WR 142,490) in the treatment of human malaria.. Science, 190 (4216): (792-4). [PMID:1105787] |
| 2. Weiss SM, Benwell K, Cliffe IA, Gillespie RJ, Knight AR, Lerpiniere J, Misra A, Pratt RM, Revell D, Upton R et al.. (2003) Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease.. Neurology, 61 (11 Suppl 6): (S101-6). [PMID:14663021] |
| 3. Gillespie RJ, Adams DR, Bebbington D, Benwell K, Cliffe IA, Dawson CE, Dourish CT, Fletcher A, Gaur S, Giles PR et al.. (2008) Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives.. Bioorg Med Chem Lett, 18 (9): (2916-9). [PMID:18406614] |
| 4. Karbwang J, White NJ. (1990) Clinical pharmacokinetics of mefloquine.. Clin Pharmacokinet, 19 (4): (264-79). [PMID:2208897] |
| 5. Wong W, Bai XC, Sleebs BE, Triglia T, Brown A, Thompson JK, Jackson KE, Hanssen E, Marapana DS, Fernandez IS et al.. (2017) Mefloquine targets the Plasmodium falciparum 80S ribosome to inhibit protein synthesis.. Nat Microbiol, 2 (17031). [PMID:28288098] |
| 6. Brasseur P, Kouamouo J, Brandicourt O, Moyou-Somo R, Druilhe P. (1988) Patterns of in vitro resistance to chloroquine, quinine, and mefloquine of Plasmodium falciparum in Cameroon, 1985-1986.. Am J Trop Med Hyg, 39 (2): (166-72). [PMID:3044155] |
| 7. Sheridan CM, Garcia VE, Ahyong V, DeRisi JL. (2018) The Plasmodium falciparum cytoplasmic translation apparatus: a promising therapeutic target not yet exploited by clinically approved anti-malarials.. Malar J, 17 (1): (465). [PMID:30541569] |
| 8. Yang Jinlan, Gao Yulan, Yang Li. (2022) Capillary-based fluorescence microsensor with polyoxometalates as nanozyme for rapid and ultrasensitive detection of artemisinin. MICROCHIMICA ACTA, 189 (1): (1-8). [PMID:34964917] [10.1007/s00604-021-05126-z] |
首页
400-620-6333
1篇引用文献 
